Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Decreases By 11.1%

Eterna Therapeutics Inc. (NASDAQ:ERNAGet Free Report) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 33,600 shares, a decline of 11.1% from the February 29th total of 37,800 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is currently 2.7 days.

Eterna Therapeutics Stock Performance

ERNA traded up $0.05 during trading hours on Tuesday, reaching $2.35. The company’s stock had a trading volume of 7,895 shares, compared to its average volume of 10,071. Eterna Therapeutics has a 52 week low of $0.84 and a 52 week high of $3.75. The firm has a market cap of $12.71 million, a PE ratio of -0.58 and a beta of 4.16. The company’s 50-day moving average is $1.91 and its 200-day moving average is $1.72. The company has a debt-to-equity ratio of 3.03, a quick ratio of 1.46 and a current ratio of 1.46.

Eterna Therapeutics (NASDAQ:ERNAGet Free Report) last released its earnings results on Thursday, March 14th. The company reported ($1.14) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million during the quarter.

Institutional Investors Weigh In On Eterna Therapeutics

Several hedge funds have recently added to or reduced their stakes in ERNA. Vanguard Group Inc. increased its position in Eterna Therapeutics by 30.6% in the 3rd quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock valued at $54,000 after buying an additional 5,830 shares in the last quarter. Sippican Capital Advisors grew its holdings in shares of Eterna Therapeutics by 30.1% in the third quarter. Sippican Capital Advisors now owns 28,100 shares of the company’s stock valued at $61,000 after acquiring an additional 6,499 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Eterna Therapeutics during the 2nd quarter valued at $26,000. Geode Capital Management LLC bought a new stake in Eterna Therapeutics in the fourth quarter worth about $45,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Eterna Therapeutics in the 4th quarter worth approximately $56,000. 70.55% of the stock is currently owned by institutional investors and hedge funds.

Eterna Therapeutics Company Profile

(Get Free Report)

Eterna Therapeutics Inc operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.

Read More

Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with's FREE daily email newsletter.